Loading clinical trials...

Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis | Clinical Trials | Clareo Health

UNKNOWNPHASE3

Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis

A Randomized Control Trial of Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) Compared With 0.25% Desoximetasone Cream (Topicorte®) in the Treatment of Scalp Psoriasis

NCT02749656•Siriraj Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate efficacy and safety of 0.25% Desoximetasone cream (Topoxy®) compare with 0.25% Desoximetasone cream (Topicorte®) in the treatment of scalp psoriasis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥ 18 years
•2. Diagnosed with scalp psoriasis by dermatologist
•3. Has scalp psoriasis Involve ≥ 10% of total scalp area and also has clinical signs, or a previous diagnosis, of psoriasis on the trunk and/or limbs
•4. Total severity of scalp psoriasis should be graded in mild to very severe according to Investigator's Global Assessment score (IGA)
•5. Clinical signs (redness, thickness, scaliness) should be scored as "Moderate" for at least 1 sign and "slight" on each of the other two signs
•6. All participants agree to participate in the study and already complete and sign consent form

Exclusion Criteria

•1. Treated with these medications before including in the study
•* Topical corticosteroid for scalp psoriasis (except emollients and shampoo) within 2 weeks
•* Very potent topical corticosteroids for psoriasis on other area or Narrow band Ultraviolet B (NB-UVB) within 2 weeks
•* Oral psoralen plus Ultraviolet A (PUVA) or oral medication (Methotrexate, Acitretin, Cyclosporine) within 4 weeks
•* Biologic agents or concomitant medication that could affect scalp psoriasis (Beta- blockers, Antimalarial drugs, Lithium ) within 6 months
•2. Has skin infection or atrophic skin on the scalp
•3. Has history of allergic reaction or hypersensitivity to 0.25% Desoximetasone
•4. Female participants with pregnancy or in lactation period
•5. Participants who unable to come for follow-up visits at hospital
•6. Participants with other underlying disease e.g. diabetes mellitus, hypertension, thyroid disease
+1 more criteria

Locations (1)

Department of dermatology Faculty of Medicine Siriraj Hospital

Bangkok, Thailand

Key Dates

Start Date

January 1, 2016

Primary Completion Date

January 1, 2018

Completion Date

December 1, 2018

Last Updated

May 1, 2017

Enrollment

105

ESTIMATED participants

Conditions

Scalp Psoriasis

Interventions

0.25% Desoximetasone cream (Topoxy®)

DRUG

0.25% Desoximetasone cream (Topicorte®)

DRUG

Placebo

DRUG

Contacts

Pichanee Chaweekulrat, M.D.

CONTACT

+6686-886-5277 pizzu43087@gmail.com

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

NCT05969223

Genital PsoriasisScalp Psoriasis

View study

COMPLETEDPHASE3

Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis

NCT01195831

Scalp Psoriasis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 1, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis

Inclusion Criteria

Exclusion Criteria

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis

Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

IL-17 Role in Variants of Psoriasis